Homologous or heterologous COVID-19 vaccine schemes : comparison of immune responses and side effects
Copyright © 2023 Elsevier Inc. All rights reserved..
Real-life data are needed regarding the appropriate time and selection of vaccination strategies, homologous or heterologous. We aimed to compare neutralizing antibody levels and side effects in different vaccination schemes. The study included 310 Health Care Workers (HCWs) vaccinated with 5 different schemes. Antispike/RBD IgG levels were measured between 28 and 60 days after the last dose. Side effects in participants were recorded, and pharmacovigilance records were reviewed from the outpatient vaccine clinic. Mean age of the participants was 38 ± 11 years of whom 226 (72.9%) were female, and 84 (27.1%) were male. After booster doses, increasing antibody levels were detected in all groups. Mean antibody levels were detected to be statistically lower in 3 doses of inactivated vaccines group. The side effects were no significant difference between groups. Booster dose administration with mRNA vaccines stands out as the most accurate strategy for those at risk of contracting severe COVID-19 and HCWs caring for this population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Diagnostic microbiology and infectious disease - 107(2023), 2 vom: 01. Okt., Seite 116017 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karaali, Rıdvan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 28.08.2023 Date Revised 28.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diagmicrobio.2023.116017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360617816 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360617816 | ||
| 003 | DE-627 | ||
| 005 | 20231226083409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diagmicrobio.2023.116017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360617816 | ||
| 035 | |a (NLM)37562205 | ||
| 035 | |a (PII)S0732-8893(23)00127-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karaali, Rıdvan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Homologous or heterologous COVID-19 vaccine schemes |b comparison of immune responses and side effects |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.08.2023 | ||
| 500 | |a Date Revised 28.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Real-life data are needed regarding the appropriate time and selection of vaccination strategies, homologous or heterologous. We aimed to compare neutralizing antibody levels and side effects in different vaccination schemes. The study included 310 Health Care Workers (HCWs) vaccinated with 5 different schemes. Antispike/RBD IgG levels were measured between 28 and 60 days after the last dose. Side effects in participants were recorded, and pharmacovigilance records were reviewed from the outpatient vaccine clinic. Mean age of the participants was 38 ± 11 years of whom 226 (72.9%) were female, and 84 (27.1%) were male. After booster doses, increasing antibody levels were detected in all groups. Mean antibody levels were detected to be statistically lower in 3 doses of inactivated vaccines group. The side effects were no significant difference between groups. Booster dose administration with mRNA vaccines stands out as the most accurate strategy for those at risk of contracting severe COVID-19 and HCWs caring for this population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BNT162b2 mRNA | |
| 650 | 4 | |a Inactivated CoronaVac | |
| 650 | 4 | |a Neutralizing antibody | |
| 650 | 4 | |a Side effects | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a Vaccine schemes | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Öykü Dinç, Harika Öykü |e verfasserin |4 aut | |
| 700 | 1 | |a İnanç Balkan, İlker |e verfasserin |4 aut | |
| 700 | 1 | |a Can, Günay |e verfasserin |4 aut | |
| 700 | 1 | |a Keskin, Elif |e verfasserin |4 aut | |
| 700 | 1 | |a Çolak, Hatice |e verfasserin |4 aut | |
| 700 | 1 | |a Daşdemir, Ferhat Osman |e verfasserin |4 aut | |
| 700 | 1 | |a Aydoğan, Okan |e verfasserin |4 aut | |
| 700 | 1 | |a Budak, Beyhan |e verfasserin |4 aut | |
| 700 | 1 | |a Kaya, Sibel Yildiz |e verfasserin |4 aut | |
| 700 | 1 | |a Kocazeybek, Bekir |e verfasserin |4 aut | |
| 700 | 1 | |a Saltoğlu, Neşe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostic microbiology and infectious disease |d 1986 |g 107(2023), 2 vom: 01. Okt., Seite 116017 |w (DE-627)NLM01262845X |x 1879-0070 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2023 |g number:2 |g day:01 |g month:10 |g pages:116017 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diagmicrobio.2023.116017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2023 |e 2 |b 01 |c 10 |h 116017 | ||